check_circleStudy Completed
Prevention of venous thromboembolism after MOS
Bayer Identifier:
12362
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
EU CT Number:
Not Available
BAY59-7939,Dose proportionality II for SPAF
Trial purpose
Please see attached Study Results Summary below
Key Participants Requirements
Sex
N/AAge
18 - 45 YearsTrial summary
Enrollment Goal
24Trial Dates
July 2009 - August 2009Phase
Phase 1Could I Receive a placebo
N/AProducts
Xarelto (Rivaroxaban, BAY59-7939)Accepts Healthy Volunteer
N/AWhere to participate
Status | Institution | Location |
---|---|---|
Completed | CRS Clinical-Research-Services Mannheim GmbH | Mannheim, 68167, Germany |
Trial design
Trial Type
InterventionalIntervention Type
N/ATrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A